Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 1 of 1 for:    NCT03536143
Previous Study | Return to List | Next Study

Topical Bercolagene Telserpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa (GEM-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03536143
Recruitment Status : Recruiting
First Posted : May 24, 2018
Last Update Posted : January 31, 2019
Information provided by (Responsible Party):
Krystal Biotech, Inc.

Brief Summary:
This study is being conducted to determine if topical bercolagene telserpavec (KB103, HSV1-COL7) can safely and effectively promote healing of DEB patient wounds (primary endpoint) and to assess change from baseline in Investigator Global Assessments and Patient Reported Outcomes (secondary endpoint).

Condition or disease Intervention/treatment Phase
Dystrophic Epidermolysis Bullosa Biological: Topical bercolagene telserpavec Phase 2

Detailed Description:
Four subjects are planned for the Phase II portion of this study: 2 adults and 2 subjects age 5 and older. Subjects are enrolled upon obtaining consent and meeting entry criteria. Three wounds are selected per subject; two will receive bercolagene telserpavec and one will receive placebo. Administrations occur daily on Days 1 through 5, and again on Days 30, 60, and 90 if there is visible wound at the original administration site. Throughout the study wounds will imaged and biopsied for safety and efficacy analyses. Subjects will be on-trial for approximately 6 months: 3 months of on-site visits followed by a 3-month at-home imaging period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Bercolagene Telserpavec (KB103), a Non-Integrating, Replication-Incompetent Herpes Simplex Virus 1 (HSV-1) Vector Expressing the Human Collagen VII (COL7) Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Actual Study Start Date : May 7, 2018
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : March 2024

Arm Intervention/treatment
Experimental: Topical bercolagene telserpavec
HSV1-COL7A1 vector (KB103)
Biological: Topical bercolagene telserpavec
Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
Other Names:
  • HSV1-COL7A1
  • KB103

Primary Outcome Measures :
  1. Wound Closure [ Time Frame: 24 weeks post treatment ]
    Change of wound surface area relative to baseline and placebo, time to wound closure relative to placebo, and duration of wound closure relative to placebo.

Secondary Outcome Measures :
  1. Investigator's Global Assessment [ Time Frame: 12 weeks post treatment ]
    Change from baseline in the Investigator's Global Assessment score

  2. Patient Reported Outcomes [ Time Frame: 12 weeks post treatment ]
    Change from baseline in PRO scales of severity and pain

  3. Presence of collagen VII [ Time Frame: 12 weeks post treatment ]
    Level of collagen VII in KB103-administered skin as measured by immunofluorescence.

  4. Presence of anchoring fibrils [ Time Frame: 12 weeks post treatment ]
    Presence of anchoring fibrils as measured by immunoelectron microscopy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of the recessive form of dystrophic epidermolysis bullosa.
  • Age

    1. 2 subjects: 18 years old or older,
    2. 2 subjects: 5 years old or older.
  • At least one wound that is between 10 and 20 cm2 in wound area.
  • Subjects, who are, in the opinion of the Investigator, able to understand the study, co-operate with the study procedures and are willing to return to the clinic for all the required follow-up visit

Exclusion Criteria:

  • The presence of medical illness expected to complicate participation
  • Serum antibodies to type collagen VII
  • Active infection in the area that will undergo injection.
  • Evidence of systemic infection.
  • Current evidence or a history of squamous cell carcinoma in the area that will undergo treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03536143

Layout table for location contacts
Contact: M. Peter Marinkovich, M.D. 650-723-6316

Layout table for location information
United States, California
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Kunju Sridhar, PhD    408-348-0614   
Principal Investigator: M. Peter Marinkovich, M.D.         
Sponsors and Collaborators
Krystal Biotech, Inc.

Layout table for additonal information
Responsible Party: Krystal Biotech, Inc. Identifier: NCT03536143    
Other Study ID Numbers: KB103-001
First Posted: May 24, 2018    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Krystal Biotech, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous
Collagen Diseases
Connective Tissue Diseases